Taxane containing regimens for metastatic breast cancer
- 21 July 2003
- reference entry
- Published by Wiley
- No. 3,p. CD003366
- https://doi.org/10.1002/14651858.cd003366
Abstract
It is generally accepted that taxanes are among the most active chemotherapy agents in the management of metastatic breast cancer. To identify and review the randomised evidence comparing taxane containing chemotherapy regimens with regimens not containing a taxane in the management of women with metastatic breast cancer. The specialised register maintained by the Editorial Base of the Cochrane Breast Cancer Group was searched on 2nd May 2003 using the codes for "advanced breast cancer", "chemotherapy". Details of the search strategy applied by the Group to create the register, and the procedure used to code references, are described in the Group's module on the Cochrane Library. Randomised trials comparing taxane-containing chemotherapy regimens with regimens not containing taxanes in women with metastatic breast cancer. Data were collected from published trials. Studies were assessed for eligiblity and quality, and data were extracted, by two independent reviewers. Hazard ratios were derived for time-to-event outcomes where possible, and a fixed effect model was used for meta-analysis. Response rates were analysed as dichotomous variables. Toxicity and quality of life data were extracted where present. Twenty eligible trials were identified of which 17 had published at least some results, and 12 had published time-to-event data. The quality of randomisation was generally not described. An estimated 2659 deaths in 3643 randomised women demonstrate a statistically significant difference in favour of taxane-containing regimens with a HR for overall survival of 0.90 (95% CI=0.84-0.97, p=0.009) and no significant heterogeneity. If the analysis is restricted to trials of firstline chemotherapy the HR changes to 0.92 and is no longer statistically significant (95% CI 0.84-1.02, p=0.12). There was also a significant difference in favour of taxanes in relation to time to progression (overall HR 0.87, 95%CI 0.81-0.93, p<0.0001) and overall response (overall OR 1.29, 95%CI 1.13-1.47, p<0.0001) however there was strong statistical evidence of heterogeneity (P<0.00001), probably reflecting the varying efficacy of the comparator regimens used in the trials. When all trials are considered, taxane-containing regimens appear to improve overall survival, time to progression and overall response in women with metastatic breast cancer. The degree of heterogeneity encountered indicates that taxane-containing regimens are more effective than some, but not all non-taxane-containing regimens.Keywords
This publication has 21 references indexed in Scilit:
- HER-2/neu Gene Amplification and Response to Paclitaxel in Patients With Metastatic Breast CancerJNCI Journal of the National Cancer Institute, 2004
- Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancerEuropean Journal Of Cancer, 2003
- Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III TrialJournal of Clinical Oncology, 2003
- Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193)Journal of Clinical Oncology, 2003
- Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failureBritish Journal of Cancer, 2002
- Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III TrialJournal of Clinical Oncology, 2002
- Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclinesBritish Journal of Cancer, 2002
- Gemcitabine, epirubicin and paclitaxel (GET) vs. 5-fluorouracil, epirubicin and cyclophosphamide (FEC) as first-line treatment in metastatic breast cancer: interim toxicity analysis of a randomised, multicenter phase iii trial of the Central European Cooperative Oncology Group (CECOG)European Journal Of Cancer, 2001
- Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancerCancer Treatment Reviews, 2000
- Randomized open-label phase III multicenter trial comparing TAXOL®/doxorubicin (AT) versus 5-fluorouracil/doxorubicin and cyclophosphamide (FAC) as a first line treatment for patients with metastatic breast cancerEuropean Journal Of Cancer, 1999